Cochrane · systematic review · CD006243
Trastuzumab containing regimens for early breast cancer
Moja, L, Tagliabue, L, Balduzzi, S, et al. · Cochrane Database of Systematic Reviews · 2012 · Cochrane Library
Breast CancerAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
5
current version
GRADE rated
5
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 0 · 0%Low 1 · 20%Moderate 1 · 20%High 3 · 60%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Trastuzumab‐containing regimens for early breast cancer
Population: HER2‐positive early breast cancer patients
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Overall survival (OS) | HR 0.66 [0.57, 0.77] | 8 studies · 9945 participants | High |
Disease free survival (DFS) | HR 0.6 [0.5, 0.71] | 8 studies · 9935 participants | High |
Congestive heart failure (CHF) | RR 5.11 [3, 8.72] | 8 studies · 10281 participants | High |
Left ventricular ejection fraction decline (LVEF) | RR 1.83 [1.36, 2.47] | 7 studies · 7939 participants | Moderate Downgraded: inconsistency, publication bias |
Brain metastasis as first site of relapse | RR 1.75 [1.29, 2.38] | 5 studies · 6881 participants | Low Downgraded: risk of bias |